---
title: 'AI accelerates IBD clinical trials through site selection.'
date: '2026-01-23'
imageUrl: 'https://picsum.photos/seed/567/1200/600'
topics:
  - "AI accelerates IBD clinical trials through site selection."
  - "AI, ML drive Human Capital Management software growth."
  - "AI/ML drives digital asset management growth."
  - "Pinewood.AI debuts AI at North American NADA show."
  - "AI accelerates IBD clinical trials via site selection."
---

# AI/ML News Updates

Stay informed with the latest developments in artificial intelligence and machine learning.

---

## AI accelerates IBD clinical trials through site selection.

PhaseV's AI platform, using causal machine learning and IBD Plexus®, significantly reduces uncertainty in IBD clinical trial site selection. This innovation accelerates trial execution by optimizing recruitment and leveraging real-time analytics.

---

## AI, ML drive Human Capital Management software growth.

AI and ML are key drivers in the Human Capital Management (HCM) software market, enabling task automation and improved employee experience. The growing gig economy also presents opportunities for HCM solutions focused on Total Workforce Management.

---

## AI/ML drives digital asset management growth.

The Digital Asset Management Software market is poised for growth, driven by AI/ML adoption for workflow optimization and metadata enhancement. Emerging opportunities lie in supporting collaborative remote work and the increasing use of 3D, AR, and VR content for e-commerce engagement.

---

## Pinewood.AI debuts AI at North American NADA show.

Pinewood.AI, a cloud-based automotive retail technology provider, will launch its Intelligence solution, Pi, and an AI-powered event assistant at its North American debut during NADA 2026. This marks the company's official entry into the North American market.

---

## AI accelerates IBD clinical trials via site selection.

PhaseV showcased how AI-driven site selection and real-time analytics, using causal machine learning, significantly reduce uncertainty and speed up IBD clinical trials. Their IBD Plexus® platform helps optimize trial execution, as demonstrated at the 2026 Crohn's & Colitis Congress®.

